Madrigal Pharmaceuticals, Inc. (MDGL) — Analyst outlook / Analyst consensus target is. Based on 23 analyst ratings, the consensus is bullish — 20 Buy, 2 Hold, 1 Sell.
The consensus price target is $705.67 (low: $527.00, high: $964.00), representing an upside of 34.4% from the current price $524.99.
Analysts estimate Earnings Per Share (EPS) of $-23.40 and revenue of $0.18B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-21.90 vs est $-23.40 (beat +6.4%). 2025: actual $-12.85 vs est $-11.04 (missed -16.4%). Analyst accuracy: 90%.
MDGL Stock — 12-Month Price Forecast
$705.67
▲ +34.42% Upside
Average Price Target
Based on 23 Wall Street analysts offering 12-month price targets for Madrigal Pharmaceuticals, Inc., the average price target is $705.67, with a high forecast of $964.00, and a low forecast of $527.00.
The average price target represents a +34.42% change from the last price of $524.99.
Highest Price Target
$964.00
Average Price Target
$705.67
Lowest Price Target
$527.00
MDGL Analyst Ratings
Buy
Based on 23 analysts giving stock ratings to Madrigal Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — MDGL
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$21.90
vs Est –$23.40
▲ 6.9% off
2025
Actual –$12.85
vs Est –$11.04
▼ 14.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — MDGL
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.180B
vs Est $0.175B
▲ 3.1% off
2025
Actual $0.958B
vs Est $0.950B
▲ 0.9% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
